Mice link neck dendritic cells to Alzheimer’s damage

New clues suggest how destructive immune cells wreak havoc in the brain:  Study in mice strengthens T cells’ ties to neurodegenerative conditions like Alzheimer’s.

A few years ago, scientists saw something surprising in the brain tissue of people who died with Alzheimer’s disease:  white blood cells that multiply in response to foreign threats and are seldom seen inside healthy brains.

Whether these so-called CD8+ killer T cells, which normally target infected cells in the body, were there to harm or help was unclear.  An answer began to emerge in 2023, when a team led by neuroscientist David Holtzman showed that in mice bred to overexpress tau — a toxic protein that builds up in the neurons of people with Alzheimer’s and several other neurodegenerative diseases — getting rid of the T cells stemmed tissue loss and preserved the mice’s cognition, even as tau kept building up.

Now, the same group has explored what prompts these cells to wreak havoc in the brain.  In a mouse study published in early September 2026 in Nature Neuroscience, Holtzman and immunology researcher Hao Hu, both at Washington University in St. Louis, report that immune cells in the lymph nodes of the neck instruct the T cells to clone themselves before they enter the brain.  Without them, the mice had far fewer cloned T cells inside their brains and experienced less neurodegeneration.  The study is “beautiful work,” says Neuroscientist Kenneth Kosik of the University of California, Santa Barbara, who studies tau; however, was not involved in the research.  It also suggests that existing drugs, developed for other conditions, might work in Alzheimer’s by shielding the brain from the destructive cells.

The new study homes in on a type of dendritic cells, immune cells that, in effect, give the killer T cells their orders.  After cutting up the invader’s proteins, the dendritic cells present the antigens as bite-size pieces that T cells can recognize.  T cells with compatible receptors can then become activated, which causes the cells to start to clone themselves, attack cells bearing the antigen, and cause inflammation.

Holtzman and Hu studied the role of dendritic cells by ensuring that half of their tau-overexpressing mice were genetically incapable of making them.  The researchers then observed mice from both groups — some 80 animals in all — through about 10 months of age, when they normally have brain damage and severe behavioral symptoms, including trouble building nests.  Both groups continued to accumulate tau; however, those lacking the dendritic cells were largely protected from neurodegeneration and behavioral problems.

The finding suggests tau, suspected of killing neurons in Alzheimer’s and other neurodegenerative diseases, does not act alone.  Tau probably leads to some injury, Holtzman thinks, “but the inflammation is really amplifying the injury.  It’s an important issue [to consider] in developing future therapies.”

Holtzman and Hu also tracked down where in the body the T cells were getting primed.  In a separate experiment, the team loaded an artificial antigen into neurons in the mice’s brains and then searched the rodents’ bodies for proliferating T cells specific to that antigen.  The researchers found that matching T cells proliferated in the neck lymph nodes of the mice, something that did not occur in mice lacking the dendritic cells.  This suggested an antigen coming from the brain was draining into those lymph nodes, where dendritic cells were picking it up and presenting it.

The finding that this process occurs in the neck, not the brain, is crucial, says neuroimmunology researcher John Lukens of the University of Virginia.  That is because it suggests tamping down the number of destructive T cells in the brain would not require a drug to cross the blood-brain barrier — a persistent challenge in developing drugs for neurodegenerative disease.

Better yet, existing drugs may be able to help.  Several treatments for multiple sclerosis work by trapping T cells in the lymph nodes, away from the brain and spinal cord.  In theory, Lukens says, these drugs “could be rapidly co-opted for the treatment of tauopathies and Alzheimer’s disease.”  The next step “would be to uncover the specific [signaling proteins] that orchestrate T cell recruitment to the brain in tau-driven neurodegenerative diseases.”

Kosik agrees that is a key question.  “How does the pathology in the nervous system talk to the T cells?” he asks.  At an April 2026 meeting, Holtzman’s colleagues suggested the T cells respond to a specific cytokine — a type of protein that triggers inflammation — produced by astrocytes and microglia, the cells that make up most of the brain’s innate immune system.  Lukens’s group, meanwhile, has identified a different protein signal.

Another urgent question is which antigen from the brain activates the T cells in the first place, and Holtzman’s study contains data that can be used by others to find out. Dementia researchers have speculated that the CD8+ T cells might be responding to old infections, to fragments of tau, or to something else entirely.  Another possibility is that they are autoreactive — and mistakenly bind to the body’s own proteins in the brain.  “This would give Alzheimer’s and related diseases an autoimmune component,” Lukens says, which could radically change how they are understood and treated.

REFERENCE:  Science; 08 SEP 2026; Jennie Erin Smith